CREATE Medicines, a biotech company developing CAR-T therapies, raises $122 million

May 14, 2026

Bayer to acquire Perfuse Therapeutics to complement ophthalmology pipeline

May 6, 2026

TIME100 Health Honors Dr. Zhen Xu for Pioneering Work in Non-Invasive Cancer Therapy

February 13, 2026

Contego Medical Announces Unprecedented 30-day Outcomes From The PERFORMANCE III TCAR-IEP Study

November 6, 2025

HistoSonics Announces $2.25B Acquisition by Consortium of Top-Tier Investors

August 7, 2025

Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi

May 23, 2025

Perfuse Therapeutics Announces Positive Results from the Completed Phase 1/2a Clinical Trial of PER-001 Intravitreal Implant in Patients with Glaucoma

May 7, 2025

Atsena gets Bain’s support in $150M Series C to thwart blindness with gene therapy

April 2, 2025

Atsena raises $150M for ocular gene therapies with Bain, Sofinnova in tow

April 2, 2025

Tune Therapeutics Completes Over $175M in Series B Financing to Advance Field-Leading Epigenome Editing Programs

January 13, 2025

Aer Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Fexlamose in Chronic Obstructive Pulmonary Disease

January 8, 2025

HistoSonics Announces Oversubscribed $102 Million Series D Financing to Scale Launch of Non-Invasive Histotripsy Platform

August 15, 2024

Endogenex™ Announces $88 Million Series C Financing to Complete Pivotal Trial of the ReCET™ System in Patients with Type 2 Diabetes

June 25, 2024

Shionogi Further Extends Infectious Disease Innovation Platform with Planned Acquisition of Qpex Biopharma, Inc.

July 25, 2023

Myeloid Therapeutics Announces $73 Million Financing to Advance mRNA-based Immunotherapy Pipeline

May 18, 2023

NewYork-Presbyterian Enrolls First Patient in National Study of Sacral Nerve Stimulation Device for Inflammatory Bowel Disease

May 3, 2023

Cardiosense, Inc., Completes $15.1 Million Series A Financing to Advance Artificial Intelligence Platform for Heart Disease

December 8, 2022

Teleflex to Expand Its Surgical Portfolio with Differentiated Stapling Technology for Bariatric Surgery

September 19, 2022

Qvella FAST System and FAST-PBC Prep Cartridge Get CE Marked and FDA Listed for In Vitro Diagnostic Use

April 25, 2022

Huma.AI Adds Post-Market Surveillance Capacity to its Unique AI-Based Healthcare Data Knowledge Platform

February 7, 2022

Aledade Acquires Advance Care Planning Company Iris Healthcare as Part of New Health Services Arm

January 25, 2022

VIGIL NEUROSCIENCE ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING

January 7, 2022

Tune Therapeutics Debuts with $40 Million to Fine-Tune the Human Genome

December 3, 2021

Morgan Stanley Expansion Capital and Ally Bridge Group Lead $135 Million Investment in Elligo

September 23, 2021

Vigil Neuroscience Completes $90 million Series B Financing to Advance a Pipeline of Microglia-targeted Medicines to Treat Rare and Common Neurodegenerative Diseases

August 18, 2021

CVRx, Inc. Announces Upsized Pricing of Initial Public Offering

June 30, 2021

RapidPulse Launches With $15 Million Series A Financing for Ischemic Stroke Therapy

June 23, 2021

Veralox Therapeutics Announces Closing Of $16.6 Million Series A Financing And Announces New Board Members

June 16, 2021

Standard Bariatrics Secures $35M in Series B Funding to Accelerate Development and Commercialization of Their First Bariatric Surgical Platform for Sleeve Gastrectomy

June 1, 2021

CROs dMed and Clinipace Merge to Accelerate Customer Success

April 28, 2021

Artizan Biosciences Closes $11 Million Series A-2 Financing and Enters Option and License Agreement with Biohaven Therapeutics

March 2, 2021

FDA approves G1 Therapeutics’ COSELA™ (TRILACICLIB): The first and only myeloprotection therapy to decrease the incidence of chemotherapy-induced myelosuppression

February 18, 2021

Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 Antagonists

February 18, 2021

BIAL Goes Global with New US Research Center and Acquisition of Promising Parkinson’s Disease Programs

October 1, 2020

Kymera Therapeutics Announces Pricing of Upsized Initial Public Offering

August 21, 2020

Trefoil Therapeutics Begins First Clinical Trial of Regenerative Treatment for Patients with Corneal Endothelial Dystrophies

August 19, 2020

Atsena Therapeutics acquires exclusive rights to Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis

August 14, 2020

Kymera Therapeutics and Sanofi Enter into Strategic Partnership to Advance Novel Protein Degrader Therapies to Patients

July 9, 2020

Shattuck Labs Announces Closing of $118 Million Series B Financing

June 15, 2020

PhaseBio Launches Clinical Trial to Evaluate PB1046 as a Treatment for Hospitalized COVID-19 Patients

May 27, 2020

AtaCor Medical Secures $25M Financing to Continue Extracardiac Pacing Development

April 28, 2020

Kymera Therapeutics Announces $102 Million Series C Financing to Advance its Protein Degrader Pipeline and Platform

March 12, 2020

HealthStream Acquires NurseGrid, #1 Rated and Top Downloaded App for Nurses

March 12, 2020

Graybug Vision Presents Preclinical Results for GB-401, a Potential Sustained-Delivery Treatment of up to Six Months for Primary Open Angle Glaucoma, at the American Glaucoma Society Annual Meeting

February 28, 2020

PhaseBio Announces European Regulatory Update for PB2452

February 11, 2020

Trefoil Therapeutics Appoints Thomas M. Tremblay, RN BSN, Vice President, Clinical Development

February 10, 2020

PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals® for PB2452

January 10, 2020

BioSpace.com selects Qpex to be among Top Life Science Companies to Watch in 2020

January 6, 2020

HistoSonics Robotic Sonic Beam Therapy Platform Wins 2019 Frost & Sullivan Innovation Award

January 6, 2020

Alkermes to Acquire Rodin Therapeutics

November 18, 2019

Sarepta pays StrideBio $48M for preclinical gene therapies

November 15, 2019

NextGen Healthcare Announces Agreement to Acquire Medfusion, Inc.

November 13, 2019

Clearside Biomedical Announces Option Exercise by REGENXBIO for Global License for Use of SCS Microinjector™ in AAV Gene Therapy Delivery

October 30, 2019

410 Medical Secures $8 Million in Series A Financing, Expands Board of Directors

October 22, 2019

Qpex Biopharma and Brii Biosciences Enter Into a Strategic Collaboration to Develop and Commercialize Antibiotics for Drug-Resistant Infections in China

October 22, 2019

A twisty career path to improve care for smokers

October 11, 2019

Graybug Vision Initiates Phase 2b (ALTISSIMO) Clinical Trial of GB-102 in Patients with Wet Age-Related Macular Degeneration

October 4, 2019

VERTEX AND RIBOMETRIX ESTABLISH STRATEGIC COLLABORATION TO DISCOVER AND DEVELOP RNA-TARGETED SMALL MOLECULE THERAPEUTICS

September 30, 2019

Graybug Vision Initiates Clinical Trial in Macular Edema Secondary to Diabetic Macular Edema or Retinal Vein Occlusion

September 18, 2019

Graybug Vision Secures $80 million of Additional Funding to Advance its Potentially Transformative Retina and Glaucoma Clinical Programs

August 20, 2019

GeneCentric Therapeutics Acquires Select ImmunoGenomics

August 20, 2019

Trefoil Therapeutics Raises $28 Million Series A to Advance Engineered FGF-1 for the Treatment of Corneal Diseases

July 16, 2019

G1 Therapeutics Announces Updated Results from Phase 2 Trial of Trilaciclib in Combination with Chemotherapy Showed Statistically Significant Improvement in Overall Survival in Women with Metastatic Triple-Negative Breast Cancer

June 18, 2019

Qpex Biopharma to Provide First Public Presentations of Preclinical Data on the Novel Ultra-Broad-Spectrum Beta-lactamase Inhibitor QPX7728 for IV and Oral Products at 2019 ASM Microbe Meeting

June 13, 2019

Artizan Biosciences Announces Corporate Progress and Financing

June 11, 2019

Vertex and Kymera Therapeutics Establish Strategic Collaboration to Discover and Develop Targeted Protein Degradation Medicines for Serious Diseases

May 15, 2019

Elligo Health Research Raises $20M to Connect More Physicians and Their Patients to Clinical Research as a Care Option

May 7, 2019

Qpex Biopharma Licenses Polymyxin Antimicrobial Program from Monash University to Address Drug-Resistant Infections

April 30, 2019

G1 Therapeutics Announces Positive Feedback from Trilaciclib End-of-Phase 2 Meeting with FDA; Expects to File NDA in 2020

April 30, 2019

HistoSonics, Non-Invasive Robotics Pioneer, Closes $54 Million Series C Financing Breakthrough medical platform offers vision of personalized tumor treatments with its novel sonic beam therapy

April 9, 2019

StrideBio and Takeda Sign Collaboration and License Agreement to Advance Novel Gene Therapies for Neurological Diseases

March 28, 2019

Full Results from PhaseBio Phase 1 Clinical Trial of PB2452 Published in the New England Journal of Medicine and Presented at the American College of Cardiology’s 68th Annual Scientific Session

March 18, 2019

Mycovia Pharmaceuticals Initiates Additional Phase 3 Clinical Study Evaluating VT-1161 for the Treatment of Vulvovaginal Candidiasis

February 27, 2019

Graybug Vision Appoints Frédéric Guerard as Chief Executive Officer Pharmaceutical Industry Veteran and Former Worldwide Business Franchise Head of Ophthalmology at Novartis

February 5, 2019

Standard Bariatrics Names Kurt Azarbarzin as Chairman of the Board of Directors

January 30, 2019

HistoSonics Selected as One of the Hottest Startups at the 2019 J.P. Morgan Healthcare Investment Conference

January 8, 2019

Ribometrix raises $30M to drug upstream RNA with small molecules

November 13, 2018

Kymera Therapeutics Announces $65 Million Series B Financing to Advance Pipeline of Targeted Protein Degraders in Oncology and Immunology

November 13, 2018

Qpex Biopharma Announces Closing of $33 Million Series A Financing and Launch of Company to Address Worldwide Problem of Drug-Resistant Infections

October 25, 2018

Clearside Biomedical Appoints Thomas A. Ciulla, M.D., MBA as Chief Medical Officer

October 25, 2018

G1 Therapeutics to Present Additional Data from Randomized Phase 2 Trial of Trilaciclib in Combination with Etoposide/Carboplatin at European Society for Medical Oncology (ESMO) 2018 Congress

October 22, 2018